International Summit on Immunotherapy and Cellular Therapy in Cancer (ICTC)
Past events
There is a growing and urgent global demand for academic continuing education of hematologists and oncologists. The development of new drugs (targeted therapies, immunotherapy, etc.) is accompanied by a growing demand for sharing experiences in order to improve the quality of patient treatment and care through the development of professional competencies and excellence. The 1st Immunotherapy and Cellular Therapy in Cancer (ICTC) International Summit will cover the following topics:
– Principles of immunotherapy
– CAR T cells procurement
– CAR T cells results in ALL, NHL, CLL and myeloma
– Management of CAR T cells toxicities
– Real life examples
– Other CAR constructs
– Emerging novel cellular therapies
January 19-20, 2019 • Hong Kong
Video recording from 1st ICTC International Summit
Session 1: Why do we need immunotherapy and novel cellular therapies
Therapeutic landscape in the treatment of relapsed B cell lympoma
Ali Bazarbachi, Lebanon
Therapeutic landscape in the treatment of relapsed myeloma
James Chim, Hong Kong
Session 2: From the bench to the bedside: The innovation zone
Mechanisms of resistance to CAR T cells
Elad Jacoby, Israel
A PDF copy of this presentation will be made available at a later time.
Biologics License Application (BLA) of a CAR T cell immunotherapy in the US
Victor Lu, USA
A PDF copy of this presentation will be made available at a later time.
Session 3a: Clinical results update (1)
Update on the results of CAR T cells in ALL
Jordan Gauthier, USA
Update on the results of CAR T cells in myeloma
Mohamad Mohty, France
CAR T cells experience from Hangzhou
He Huang, China
Session 3b: Clinical results update (2)
CAR T cells experience from Spain
Alvaro Ispizua, Spain
Management of CAR-T cell toxicities
Mohamad Mohty, France
Jordan Gauthier, USA
Biologics License Application (BLA) of a CAR T cell immunotherapy in the US
Victor Lu, USA
A PDF copy of this presentation will be made available at a later time.
Session 4: Practical management
CAR T cells development in solid cancers
Zonghail Li, China
Cell procurement for CAR T cells
Christian Chabannon, France
Update on the results of CAR T cells in ALL
Miguel-Angel Perales, USA
Session 5: Perspectives in cellular therapy
CAR T cells combined with stem cell transplantation
Didier Blaise, France
Taking CART from theory to reality – the Novartis experience
Matthew Robson, USA
g/d T cells for immunotherap
Jurgen Kuball, Netherlands
Allogeneic CAR T cells
Wasim Qasim, United-Kingdom
NK CAR cells
Mickey Koh, Singapore/UK